The latest price target for Alterity Therapeutics (NASDAQ:ATHE) was reported by Maxim Group on January 30, 2025. The analyst firm set a price target for $12.00 expecting ATHE to rise to within 12 months (a possible 142.91% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for Alterity Therapeutics (NASDAQ:ATHE) was provided by Maxim Group, and Alterity Therapeutics maintained their buy rating.

There is no last upgrade for Alterity Therapeutics

There is no last downgrade for Alterity Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alterity Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alterity Therapeutics was filed on January 30, 2025 so you should expect the next rating to be made available sometime around January 30, 2026.

While ratings are subjective and will change, the latest Alterity Therapeutics (ATHE) rating was a maintained with a price target of $8.00 to $12.00. The current price Alterity Therapeutics (ATHE) is trading at is $4.94, which is out of the analyst’s predicted range.